Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C
Authors:
Open Access
- 2 October 2003
- journal article
- clinical trial
- Published by Springer Nature in Leukemia
- Vol. 17 (12) , 2392-2400
Abstract
We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive imatinib (n=69) or interferon (IFN)/Ara-C (n=70). The response was sequentially monitored by cytogenetics from bone marrow metaphases (n=803) and qualitative and quantitative RT-PCR from peripheral blood samples (n=1117). Complete cytogenetic response (CCR) was achieved in 60 (imatinib, 87%) vs 10 patients (IFN/Ara-C, 14%) after a median observation time of 24 months. Within the first year after CCR, best median ratio BCR-ABL/ABL was 0.087%, (imatinib, n=48) vs 0.27% (IFN/Ara-C, n=9, P=0.025). BCR-ABL was undetectable in 25 cases by real-time PCR, but in only four patients by nested PCR. Median best response in patients with relapse after CCR was 0.24% (n=3) as compared to 0.029% in patients with continuous remission (n=52, P=0.029). We conclude that (i) treatment with imatinib in newly diagnosed CML patients is associated with a rapid decrease of BCR-ABL transcript levels; (ii) nested PCR may reveal residual BCR-ABL transcripts in samples that are negative by real-time PCR; (iii) BCR-ABL transcript levels parallel cytogenetic response, and (iv) imatinib is superior to IFN/Ara-C in terms of the speed and degree of molecular responses, but residual disease is rarely eliminated.Keywords
This publication has 36 references indexed in Scilit:
- Detection and quantification of residual disease in chronic myelogenous leukemiaLeukemia, 2000
- Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCRLeukemia, 1999
- Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a ‘real time’ quantitative RT-PCR assayLeukemia, 1999
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real‐time quantitative RT‐PCRBritish Journal of Haematology, 1998
- Molecular response of CML patients treated with interferon‐α monitored by quantitative Southern blot analysisBritish Journal of Haematology, 1997
- Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemiaThe Lancet, 1993
- POLYMERASE CHAIN REACTION FOR DETECTION OF RESIDUAL LEUKAEMIAThe Lancet, 1989
- Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22Cell, 1984
- A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 1973